A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response

Background: Intracellular copper homeostasis requires a complex system. It has shown considerable prospects for intervening in the tumor microenvironment (TME) by regulating copper homeostasis and provoking cuproptosis. Their relationship with hepatocellular carcinoma (HCC) remains elusive. Methods: In TCGA and ICGC datasets, LASSO and multivariate Cox regression were applied to obtain the signature on the basis of genes associated with copper homeostasis and cuproptosis. Bioinformatic tools were utilized to reveal if the signature was correlated with HCC characteristics. Single-cell RNA sequencing data analysis identified differences in tumor and T cells’ pathway activity and intercellular communication of immune-related cells. Real-time qPCR analysis was conducted to measure the genes’ expression in HCC and adjacent normal tissue from 21 patients. CCK8 assay, scratch assay, transwell, and colony formation were conducted to reveal the effect of genes on in vitro cell proliferation, invasion, migration, and colony formation. Results: We constructed a five-gene scoring system in relation to copper homeostasis and cuproptosis. The high-risk score indicated poor clinical prognosis, enhanced tumor malignancy, and immune-suppressive tumor microenvironment. The T cell activity was markedly reduced in high-risk single-cell samples. The high-risk HCC patients had a better expectation of ICB response and reactivity to anti-PD-1 therapy. A total of 156 drugs were identified as potential signature-related drugs for HCC treatment, and most were sensitive to high-risk patients. Novel ligand-receptor pairs such as FASLG, CCL, CD40, IL2, and IFN-Ⅱ signaling pathways were revealed as cellular communication bridges, which may cause differences in TME and immune function. All crucial genes were differentially expressed between HCC and paired adjacent normal tissue. Model-constructed genes affected the phosphorylation of mTOR and AKT in both Huh7 and Hep3B cells. Knockdown of ZCRB1 impaired the proliferation, invasion, migration, and colony formation in HCC cell lines. Conclusion: We obtained a prognostic scoring system to forecast the TME changes and assist in choosing therapy strategies for HCC patients. In this study, we combined copper homeostasis and cuproptosis to show the overall potential risk of copper-related biological processes in HCC for the first time.

[1]  J. Min,et al.  Copper homeostasis and cuproptosis in health and disease , 2022, Signal Transduction and Targeted Therapy.

[2]  Lin Sun,et al.  A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma , 2022, Scientific Reports.

[3]  Shaffer R S Mok,et al.  Glycolysis-related gene dihydrolipoamide acetyltransferase promotes poor prognosis in hepatocellular carcinoma through the Wnt/β-catenin and PI3K/Akt signaling pathways , 2022, Annals of translational medicine.

[4]  Jinfeng Zhu,et al.  Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma , 2022, Frontiers in Immunology.

[5]  W. Li,et al.  Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma , 2022, Frontiers in Immunology.

[6]  Zhen Zhang,et al.  Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma , 2022, Frontiers in Immunology.

[7]  Jian Zheng,et al.  A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5 , 2022, Journal of experimental & clinical cancer research : CR.

[8]  Lingmin Xie,et al.  A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma , 2022, Genes.

[9]  T. Golub,et al.  Copper induces cell death by targeting lipoylated TCA cycle proteins , 2022, Science.

[10]  V. Oliveri.  Selective Targeting of Cancer Cells by Copper Ionophores: An Overview , 2022, Frontiers in Molecular Biosciences.

[11]  Laiyu Liu,et al.  COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. , 2022, Journal of hepatology.

[12]  Howard Y. Chang,et al.  Toward a better understanding of T cells in cancer. , 2021, Cancer cell.

[13]  R. Squitti,et al.  Copper in tumors and the use of copper-based compounds in cancer treatment. , 2021, Journal of inorganic biochemistry.

[14]  P. Pandolfi,et al.  Copper Promotes Tumorigenesis by Activating the PDK1‐AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner , 2021, Advanced science.

[15]  Z. Dvořák,et al.  Copper(II) Complexes Containing Natural Flavonoid Pomiferin Show Considerable In Vitro Cytotoxicity and Anti-inflammatory Effects , 2021, International journal of molecular sciences.

[16]  M. Eason,et al.  Obscurin: A multitasking giant in the fight against cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[17]  M. Harrison,et al.  LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types , 2021, Journal for ImmunoTherapy of Cancer.

[18]  Asher Mullard.  Restoring IL-2 to its cancer immunotherapy glory , 2021, Nature Reviews Drug Discovery.

[19]  R. Lencioni,et al.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[20]  Hongmin Chen,et al.  Inhibiting the PI3K/AKT/mTOR signalling pathway with copper oxide nanoparticles from Houttuynia cordata plant: attenuating the proliferation of cervical cancer cells , 2021, Artificial cells, nanomedicine, and biotechnology.

[21]  M. Yuen,et al.  Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis , 2020, Hepatology.

[22]  Feng Zhang,et al.  Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26 , 2020, Cell Death & Disease.

[23]  A. Willis,et al.  Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases , 2020, Clinical Cancer Research.

[24]  J. Trapani,et al.  Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion , 2020, Cancer Research.

[25]  W. Zhang,et al.  CDKN2A inhibits cell proliferation and invasion in cervical cancer through LDHA-mediated AKT/mTOR pathway , 2020, Clinical and Translational Oncology.

[26]  Xiaozhong Wang,et al.  Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells , 2020, Nature Communications.

[27]  L. Bubacco,et al.  Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant? , 2020, Biomolecules.

[28]  P. Wittung-Stafshede,et al.  Evaluation of copper chaperone ATOX1 as prognostic biomarker in breast cancer , 2020, Breast Cancer.

[29]  Yuan Ren,et al.  ATPase copper transporter A, negatively regulated by miR‐148a‐3p, contributes to cisplatin resistance in breast cancer cells , 2020, Clinical and translational medicine.

[30]  Markus List,et al.  Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data. , 2020, Methods in molecular biology.

[31]  R. Vonderheide.  CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.

[32]  Xing Tang,et al.  Doxorubicin intercalated copper diethyldithiocarbamate functionalized layered double hydroxide hybrid nanoparticles for targeted therapy of hepatocellular carcinoma. , 2019, Biomaterials science.

[33]  M. Devereux,et al.  Cu(ii) phenanthroline-phenazine complexes dysregulate mitochondrial function and stimulate apoptosis. , 2019, Metallomics : integrated biometal science.

[34]  Q. Ye,et al.  Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. , 2019, American journal of cancer research.

[35]  D. Feldser,et al.  Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma , 2019, bioRxiv.

[36]  Xia Li,et al.  TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. , 2018, Cancer research.

[37]  Yani Liu,et al.  Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity. , 2018, European journal of medicinal chemistry.

[38]  M. Ushio-Fukai,et al.  Copper transporters and copper chaperones: roles in cardiovascular physiology and disease. , 2018, American journal of physiology. Cell physiology.

[39]  Xiukun Lin,et al.  Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2. , 2018, Nanomedicine.

[40]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[41]  K. Chakraborty,et al.  Cellular copper homeostasis: current concepts on its interplay with glutathione homeostasis and its implication in physiology and human diseases. , 2017, Metallomics : integrated biometal science.

[42]  T. Hambley,et al.  Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells , 2017, JBIC Journal of Biological Inorganic Chemistry.

[43]  J. Lowe,et al.  Dissecting copper homeostasis in diabetes mellitus , 2017, IUBMB life.

[44]  G. Inesi.  Molecular features of copper binding proteins involved in copper homeostasis , 2017, IUBMB life.

[45]  O. Stål,et al.  Defining the human copper proteome and analysis of its expression variation in cancers. , 2017, Metallomics : integrated biometal science.

[46]  Matthew S. Johnson,et al.  The diagnosis and treatment of hepatocellular carcinoma. , 1998, Seminars in diagnostic pathology.

[47]  IFNγ Mutations Prompt CTLA-4 Inhibitor Resistance. , 2017, Cancer discovery.

[48]  S. K. Choudhuri,et al.  A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[49]  Bin Zhang,et al.  Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma , 2015, Oncotarget.

[50]  A. McEwan,et al.  The Role of Copper and Zinc Toxicity in Innate Immune Defense against Bacterial Pathogens* , 2015, The Journal of Biological Chemistry.

[51]  Yun Liu,et al.  Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. , 2014, Cancer letters.

[52]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[53]  A. Hauschild,et al.  Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  E. Mroz,et al.  MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. , 2013, Oral oncology.

[55]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[56]  J. Chiang,et al.  Tumor-Derived Chemokine CCL5 Enhances TGF- b – Mediated Killing of CD8 þ T Cells in Colon Cancer by T-Regulatory Cells , 2012 .

[57]  J. Fernández-Piqueras,et al.  Targeting the Fas/FasL signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[58]  Jeong-Won Lee,et al.  Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. , 2011, Gynecologic oncology.

[59]  D. Hanahan,et al.  Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. , 2010, Cancer cell.

[60]  B. Stiles.  PI-3-K and AKT: Onto the mitochondria. , 2009, Advanced drug delivery reviews.

[61]  S. O’Day,et al.  Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[63]  S. Merajver,et al.  A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. , 2008, The Annals of thoracic surgery.

[64]  M. Ushio-Fukai,et al.  Novel Role of Antioxidant-1 (Atox1) as a Copper-dependent Transcription Factor Involved in Cell Proliferation* , 2008, Journal of Biological Chemistry.

[65]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  D. Thiele,et al.  Mechanisms for copper acquisition, distribution and regulation. , 2008, Nature chemical biology.

[67]  H. Hsu,et al.  Changes of serum copper and zinc levels in patients with nasopharyngeal carcinoma by radiotherapy , 1994, Biological Trace Element Research.

[68]  David C. Smith,et al.  Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer , 2007, Oncology.

[69]  Q Ping Dou,et al.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.

[70]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[71]  Daniel F. Brayton,et al.  Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. , 2004, Journal of medicinal chemistry.

[72]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[73]  Myriam Rochdi,et al.  Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.

[74]  J. Li,et al.  Cupric nitrilotriacetate-induced apoptosis in HL-60 cells association with lipid peroxidation, release of cytochrome C from mitochondria, and activation of caspase-3. , 1999, Free radical biology & medicine.

[75]  F. Soncin,et al.  Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. , 1997, Biochemical and biophysical research communications.

[76]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .